Simcyp Papers RSS Feed

Rostami-Hodjegan A, Nurminen S, Jackson PR & Tucker GT

Sun, 1 Dec 1996 00:00:00 GMT

Caffeine metabolic ratios as markers of enzyme activity: a theoretical assessment.
Pharmacogenetics
6(2), 121-49, April 1996.

Tucker GT, Rostami-Hodjegan A & Jackson PR

Tue, 1 Dec 1998 00:00:00 GMT

The determination of drug metabolising enzyme activity in vivo: pharmacokinetics and statistical issues.
Xenobiotica
28(12), 1255-1273, December 1998.

Rostami-Hodjegan A, Kromer HK & Tucker GT

Tue, 1 Jun 1999 00:00:00 GMT

In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity.
Pharmacogenetics
9(3), 277-286, June 1999.

Rostami-Hodjegan A, Funck-Brentano C, Kromer HK & Tucker GT

Tue, 1 Jun 1999 00:00:00 GMT

In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity.
British Journal of Clinical Pharmacology
47, 577-578, 1999.

Tooley A, Rostami-Hodjegan A, Lennard MS & Tucker GT

Wed, 1 Dec 1999 00:00:00 GMT

Acute inhibition of methadone metabolism by ritonavir: projection of interaindividual variability from in vitro data.
British Journal of Clinical Pharmacology
48, 883-884, 1999.

Wilson ZE, Tooley A, Rostami-Hodjegan A, Ellis SW & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

Determining values for human microsomal protein per gram of liver.
Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology A2, 55(4), 418-419, April 2003.

Proctor NJ, Rostami-Hodjegan A & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

ISEF: an intersystem extrapolation factor for use with recombinant cytochrome P450 expressed systems.
Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology A35, 55(4), 437-438, April 2003.

Proctor NJ, Rostami-Hodjegan A & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

In vitro prediction of population in vivo drug clearance using updated
scaling factors.
Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology A49, 55(4), 445, April 2003.

Johnson TN, Sabzghabaee A, Rostami-Hodjegan A & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

Prediction of age related changes in midazolam clearance in children
using SIMCYP.
Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology A26, 55(4), 432-433, April 2003.

Moghadamnia AA, Rostami-Hodjegan A, Abdul-Manap R, Wright CE, Morice AH & Tucker GT

Tue, 1 Jul 2003 00:00:00 GMT

Physiologically based modelling of inhibition of metabolism to assess the relative potency of drug and metabolite: dextromethorphan vs dextrorphan using quinidine Inhibition. British Journal of Clinical Pharmacology 56(1), 57-67, July 2003.

Yang J, Kjellsson M, Rostami-Hodjegan A & Tucker GT

Wed, 1 Oct 2003 00:00:00 GMT

The effects of dose staggering on metabolic drug-drug interactions.
European Journal of Pharmaceutical Sciences
20(2), 223-232, October 2003.

Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW & Tucker GT

Wed, 1 Oct 2003 00:00:00 GMT

Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. British Journal of Clinical Pharmacology 56(4), 433-440, October 2003.

Rowland-Yeo K, Rostami-Hodjegan A & Tucker GT

Mon, 1 Dec 2003 00:00:00 GMT

Abundance of cytochromes P450 in human liver: a meta-analysis.
British Pharmacological Society Winter Meeting
University of London, December 2003.

Wilson ZE, Tooley A, Rostami-Hodjegan A, Ellis SW & Tucker GT

Mon, 1 Dec 2003 00:00:00 GMT

Reference values for the amount of microsomal protein and number of hepatocytes per gram of human liver.
Drug Metabolism Reviews
A200, 35(S1), 100, April 2003.

Proctor NJ, Rostami-Hodjegan A & Tucker GT

Mon, 1 Dec 2003 00:00:00 GMT

Sources of variability associated with quantitative predictions of drug clearance from recombinant CYP enzymes.
Drug Metabolism Reviews
A202, 35(S1), 101, April 2003.

Proctor NJ, Tucker GT & Rostami-Hodjegan A

Sun, 1 Feb 2004 00:00:00 GMT

Prediction of clearance from recombinantly expressed CYPs: Intersystem extrapolation factor (ISEF).
Xenobiotica
34(2), 151-178, February 2004.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Sat, 1 May 2004 00:00:00 GMT

Prediction of drug clearance and its variability in neonates, infants and
children using Simcyp. European Society for Developmental, Perinatal and Paediatric
Pharmacology, 9th Congress June 16th-19th 2004, Marburg, Germany.
Abstract published in: Paediatric and Perinatal Drug Therapy
L23, 6(1), 51, May 2004.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Sat, 1 May 2004 00:00:00 GMT

A comparison of methods to predict drug clearance in neonates,
infants and children.
Proceedings of the British Pharmacological Society December 16th-18th 2003, GKT School of Biomedical Sciences,
King’s College London, Guy’s Campus.
Abstract published in: British Journal of Clinical Pharmacology
A23, 57(5), 677-678, May 2004.

Tucker GT

Thu, 1 Jul 2004 00:00:00 GMT

Pharmacogenetics - expectations and reality.
British Medical Journal
329(7456), 4-6, July 2004.

Yang J, Tucker GT & Rostami-Hodjegan A

Fri, 1 Oct 2004 00:00:00 GMT

Cytochrome P450 3A expression and activity in the human small intestine.
Clinical Pharmacology & Therapeutics
76(4), 391, October 2004.

Tucker GT

Fri, 1 Oct 2004 00:00:00 GMT

Predicting drug-drug interactions: in vitro veritas?
EUFEPS 2004 - 8th European Congress of Pharmaceutical Sciences October 17th-20th 2004, Brussels, Belgium.
Abstract published in: European Journal of Pharmaceutical Sciences
SS5-3, 23(Supplement 1), 13, October 2004.

Rowland-Yeo K, Howgate EM, Tucker GT & Rostami-Hodjegan A

Wed, 1 Dec 2004 00:00:00 GMT

Predicting the clearance of CYP2C9 substrates.
Drug Metabolism & Disposition
32(12),1522 (author reply 1523), December 2004.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Wed, 1 Dec 2004 00:00:00 GMT

Prediction of drug clearance from in vitro data for 10 drugs in neonates, infants and children using Simcyp.
Drug Metabolism Reviews
A680, 36(Supplement 1), 340, December 2004.

Özdemir M, Aktan Y, Rostami-Hodjegan A, Crewe KH & Tucker GT

Wed, 1 Dec 2004 00:00:00 GMT

Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
Journal of Clinical Pharmacology
44(12), 1398-1404, December 2004.

Rostami-Hodjegan A & Tucker GT

Wed, 1 Dec 2004 00:00:00 GMT

In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions.
Drug Discovery Today: Technologies
1(4), 441-448, December 2004.

Johnson TN

Wed, 1 Jun 2005 00:00:00 GMT

Modelling approaches to dose estimation in children.
British Journal of Clinical Pharmacology
59(6), 663-669, June 2005.

Yang J, Jamei M, Rowland Yeo K, Tucker GT & Rostami-Hodjegan A

Tue, 1 Nov 2005 00:00:00 GMT

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.
European Journal of Pharmaceutical Sciences
26(3-4), 334-340, November 2005.

Johnson TN, Tucker GT, Tanner MS & Rostami-Hodjegan A

Thu, 1 Dec 2005 00:00:00 GMT

Changes in liver volume from birth to adulthood: a meta analysis.
Liver Transplantation
12(11), 1481-1493, December 2005.

Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT & Rostami-Hodjegan A

Sat, 1 Apr 2006 00:00:00 GMT

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.
Current Drug Metabolism
7(3), 315-334, April 2006.

Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of in vivo drug clearance from in vitro data.
II: Potential inter-ethnic differences.
Xenobiotica
36(6), 499-513, June 2006.

Howgate EM, Rowland-Yeo K, Proctor NJ, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of in vivo drug clearance from in vitro data.
I: Impact of inter-individual variability.
Xenobiotica
36(6), 473-497, June 2006.

Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Sat, 1 Jul 2006 00:00:00 GMT

Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.
Xenobiotica
36(7), 567-580, July 2006.

Yang J, Jamei M, Heydari A, Rowland-Yeo K, de la Torre R, Farre M, Tucker GT & Rostami-Hodjegan A

Wed, 1 Nov 2006 00:00:00 GMT

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Journal of Psychopharmacology
20(6), 842-849, November 2006.

Van LM, Heydari A, Yang J, Hargreaves J, Rowland-Yeo K, Lennard MS, Tucker GT & Rostami-Hodjegan A

Wed, 1 Nov 2006 00:00:00 GMT

The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Journal of Psychopharmacology
20(6), 834-841, November 2006.

Johnson TN, Rostami-Hodjegan A & Tucker GT

Thu, 30 Nov 2006 00:00:00 GMT

Prediction of clearance of eleven drugs and associated variability in neonates, infants and children.
Clinical Pharmacokinetics
45(9), 931-956, September 2006.

Christensen H, Baker M, Tucker GT & Rostami-Hodjegan A

Fri, 1 Dec 2006 00:00:00 GMT

Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data.
Journal of Pharmaceutical Sciences
95(12), 2778-2787, December 2006.

Barter ZE, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lipscomb JB, Pelkonen OR, Tucker GT & Rostami-Hodjegan A

Tue, 2 Jan 2007 00:00:00 GMT

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Current Drug Metabolism
8(1), 33-45, January 2007.

Dickinson GL, Rezaee S, Proctor NJ, Lennard MS, Tucker GT & Rostami-Hodjegan A

Tue, 2 Jan 2007 00:00:00 GMT

Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphisms on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Journal of Clinical Pharmacology
47(2), 175-186, February 2007.

Dickinson GL, Lennard MS, Tucker GT & Rostami-Hodjegan A

Mon, 29 Jan 2007 00:00:00 GMT

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies - CYP2C9 and warfarin as an example.
British Journal of Clinical Pharmacology
64(1), 14-26, July 2007.

Rostami-Hodjegan A & Tucker GT

Mon, 29 Jan 2007 00:00:00 GMT

Simulation and prediction of in vivo metabolic drug clearance from in vitro data.
Nature Reviews Drug Discovery
6(2), 140-148, February 2007.

Van LM, Swales J, Hammond C, Wilson C, Hargreaves JA & Rostami-Hodjegan A

Mon, 19 Feb 2007 00:00:00 GMT

Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
European Journal of Pharmaceutical Sciences
31(1), 53-61, May 2007.

Yang J, Jamei M, Rowland-Yeo K, Rostami-Hodjegan A & Tucker GT

Tue, 6 Mar 2007 00:00:00 GMT

Misuse of the well-stirred model of hepatic drug clearance.
Drug Metabolism & Disposition
35(3), 501-502, March 2007.

Van LM, Hargreaves JA, Lennard MS, Tucker GT & Rostami-Hodjegan A.

Tue, 22 May 2007 00:00:00 GMT

Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
European Journal of Pharmaceutical Sciences
32(1), 8-16, September 2007.

Yang J, Jamei M, Rowland Yeo K, Tucker GT & Rostami-Hodjegan A

Mon, 11 Jun 2007 00:00:00 GMT

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.
European Journal of Pharmaceutical Sciences
31(3-4), 232-241, July 2007.

Yang J, Jamei M, Rowland Yeo K, Tucker GT & Rostami-Hodjegan A

Tue, 2 Oct 2007 00:00:00 GMT

Prediction of intestinal first-pass drug metabolism.
Current Drug Metabolism
8(7), 676-684, October 2007.

Perrett HP, Barter ZE, Jones BC, Yamazaki H, Tucker GT & Rostami-Hodjegan A

Fri, 12 Oct 2007 00:00:00 GMT

Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes.
Drug Metabolism & Disposition
35(10), 1733-1736, October 2007.

Yang J, Liao M, Shou M, Jamei M, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Wed, 25 Jun 2008 00:00:00 GMT

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Current Drug Metabolism 9(5), 384-394, June 2008.

Johnson TN

Mon, 21 Jul 2008 00:00:00 GMT

The problems in scaling adult drug doses to children.
Archives of Disease in Childhood 93(3), 207-211, March 2008.

Johnson TN & Thomson M

Mon, 21 Jul 2008 00:00:00 GMT

Intestinal metabolism and transport of drugs in children: the effects of age
and disease.
Journal of Pediatric Gastroenterology & Nutrition 47(1), 3-10, July 2008.

Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC & Rostami-Hodjegan A

Mon, 1 Dec 2008 00:00:00 GMT

Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metabolism & Disposition 36(12), 2405-2409, December 2008.

Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A & Lennard MS

Mon, 1 Dec 2008 00:00:00 GMT

CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metabolism & Pharmacokinetics 23(2), 101-105, April 2008.

Van LM, Sarda S, Hargreaves JA & Rostami-Hodjegan A

Mon, 26 Jan 2009 00:00:00 GMT

Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism.
Journal of Pharmaceutical Sciences
98(2), 763-771, February 2009.

Jamei M, Marciniak S, Feng K, Barnett A, Tucker G & Rostami-Hodjegan A

Mon, 9 Feb 2009 00:00:00 GMT

The Simcyp® population-based ADME simulator. Expert Opinion on Drug Metabolism & Toxicology 5(2), 211-223, February 2009.

Jamei M, Dickinson GL & Rostami-Hodjegan A

Mon, 2 Mar 2009 00:00:00 GMT

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘Bottom-Up’ vs ‘Top-Down’ recognition of covariates. Drug Metabolism & Pharmacokinetics 24(1), 53-75, 2009.

Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A & Tucker GT

Tue, 21 Apr 2009 00:00:00 GMT

Population-based mechanistic prediction of oral drug absorption. The AAPS Journal 11(2), 225-237, June 2009.

Almond LM, Yang J, Jamei M, Tucker GT & Rostami-Hodjegan A

Fri, 10 Jul 2009 00:00:00 GMT

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Current Drug Metabolism 10(4), 420-432, May 2009.

Johnson TN, Kerbusch T, Jones B, Tucker GT, Rostami-Hodjegan A & Milligan PA

Fri, 10 Jul 2009 00:00:00 GMT

Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharmaceutical Statistics 8(3), 186-202, July-September 2009.

Rowland-Yeo K, Jamei M, Yang J, Tucker GT & Rostami-Hodjegan A

Thu, 28 Jan 2010 00:00:00 GMT

Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. European Journal of Pharmaceutical Sciences In Press, 2010.

Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A.

Wed, 24 Feb 2010 00:00:00 GMT

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clinical Pharmacokinetics 49(3), 189-206, March 2010.